BridgeBio Pharma BBIO CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's capex?
- BridgeBio Pharma (BBIO) reported capex of $69K in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's capex?
- Over 4 years (2021 to 2025), BridgeBio Pharma's capex has grown at a -46.4% compound annual growth rate (CAGR), from $13.25M to $1.1M.
- What does capex mean?
- Cash spent on physical assets like buildings, equipment, and machinery.
- How do you interpret capex?
- High spending suggests capacity expansion, while low spending may indicate an asset-light model or deferred maintenance.
- How does capex compare across companies?
- Biotech companies typically have lower CapEx compared to manufacturing firms due to outsourced production models.